Spondyloarthritis & psoriatic arthritis
Ustekinumab Safety in Pregnancy: A Comprehensive Review
Authors' conclusion
We show that, to date, studies have not identified an excess risk of adverse pregnancy outcomes among women exposed to ustekinumab in pregnancy, with few exposed pregnancies and potential for some bias.
Study context
- Population
- Women exposed to ustekinumab (IL-12/23 inhibitor) in pregnancy, with inflammatory bowel diseases (IBD), psoriasis or PsA; animal studies, case reports, case series, observational studies and clinical practice guidelines
- Outcome
- Adverse pregnancy outcomes with ustekinumab exposure
Main finding
As reported in the abstract
- No excess risk of adverse pregnancy outcomes identified to date among women exposed to ustekinumab in pregnancy, with few exposed pregnancies and potential for some bias
- Clinical guidelines conflicted on whether to continue or discontinue ustekinumab
Original publication
Ustekinumab Safety in Pregnancy: A Comprehensive Review. Arthritis Care Res (Hoboken). Published 16 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →